Aspirin: 120 years of innovation, 2017 Scientific Conference, Berlin

The Sanger Institute and personalised genomics

Worrying results from genotyping quality assessments

Focus on screening, not biomarkers

Inequalities in immuno-oncology access across Europe

Creating a culture of shared data

Developing drugs for personalised medicine

Next generation sequencing identifies smoldering multiple myeloma patients with a high risk of disease progression

The Innovative Medicines Initiative

Daratumumab for patients with multiple myeloma

Venetoclax plus rituximab for patients with relapsed / refractory CLL

Daratumumab plus bortezomib, melphalan, and prednisone versus bortezomib, melphalan, and prednisone for multiple myeloma